Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-based precision combination therapy umbrella study after immunotherapy failure in esophageal or head and neck squamous cell carcinoma
ChiCTR2200057866Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dalpiciclib, famitinib, cetuximab and fluzoparib in Esophageal Squamous Cell Carcinoma (ESCC) and head and neck squamous cell carcinoma (HNSCC) (3 cohorts), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: objective response rate. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
dalpiciclibfamitinibcetuximabfluzoparib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2200057866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057866.